Literature DB >> 28177089

Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.

Eric Artiges1,2, Claire Leroy1,3, Manon Dubol1, Marie Prat1, Audrey Pepin1, Audrey Mabondo1, Renaud de Beaurepaire4, Béatrice Beaufils5, Jean-Pierre Korwin6, André Galinowski1, Marc-Antoine D'Albis7, Maria-João Santiago-Ribeiro8, Bernard Granger1,9, Eleni T Tzavara1,9,10, Jean-Luc Martinot1, Christian Trichard1,6.   

Abstract

Neuroimaging studies investigating dopamine (DA) function widely support the hypothesis of presynaptic striatal DA hyperactivity in schizophrenia. However, published data on the striatal DA transporter (DAT) appear less consistent with this hypothesis, probably partly due to methodological limitations. Moreover, DAT in extrastriatal regions has been very poorly investigated in the context of schizophrenia. In order to address these issues, we used a high resolution positron emission tomograph and the selective DAT radioligand [11C]PE2I, coupled with a whole brain voxel-based analysis method to investigate DAT availability in striatal but also extra-striatal regions in 21 male chronic schizophrenia patients compared to 30 healthy male controls matched by age. We found higher DAT availability in schizophrenia patients in midbrain, striatal, and limbic regions. DAT availability in amygdala/hippocampus and putamen/pallidum was positively correlated with hallucinations and suspiciousness/persecution, respectively. These results are consistent with an increase of presynaptic DA function in patients with schizophrenia, and support the involvement of both striatal and extrastriatal DA dysfunction in positive psychotic symptoms. The study also highlights the whole brain voxel-based analysis method to explore DA dysfunction in schizophrenia.
© The Author 2017. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  DAT; neuroimaging; positive symptoms; psychosis

Mesh:

Substances:

Year:  2017        PMID: 28177089      PMCID: PMC5581903          DOI: 10.1093/schbul/sbw192

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  58 in total

1.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

2.  Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.

Authors:  H Hall; C Halldin; D Guilloteau; S Chalon; P Emond; J Besnard; L Farde; G Sedvall
Journal:  Neuroimage       Date:  1999-01       Impact factor: 6.556

3.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

4.  Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy.

Authors:  Ikuo Odano; Andrea Varrone; Ivanka Savic; Carolina Ciumas; Per Karlsson; Aurelija Jucaite; Christer Halldin; Lars Farde
Journal:  Neuroimage       Date:  2011-10-28       Impact factor: 6.556

Review 5.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

6.  Amygdala Hyperactivity at Rest in Paranoid Individuals With Schizophrenia.

Authors:  Amy E Pinkham; Peiying Liu; Hanzhang Lu; Michael Kriegsman; Claire Simpson; Carol Tamminga
Journal:  Am J Psychiatry       Date:  2015-03-27       Impact factor: 18.112

7.  Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain.

Authors:  F I Tarazi; K Zhang; R J Baldessarini
Journal:  Neurosci Lett       Date:  2000-06-23       Impact factor: 3.046

8.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.

Authors:  J Lavalaye; D H Linszen; J Booij; P M Dingemans; L Reneman; J B Habraken; B P Gersons; E A van Royen
Journal:  Schizophr Res       Date:  2001-01-15       Impact factor: 4.939

9.  Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography.

Authors:  Hiroshi Ito; Hidehiko Takahashi; Ryosuke Arakawa; Harumasa Takano; Tetsuya Suhara
Journal:  Neuroimage       Date:  2007-09-19       Impact factor: 6.556

10.  Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.

Authors:  Aurelija Jucaite; Ikuo Odano; Hans Olsson; Stefan Pauli; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-03       Impact factor: 9.236

View more
  6 in total

1.  Activation of brainstem and midbrain nuclei during cognitive control in medicated patients with schizophrenia.

Authors:  Stefanie Köhler; Gerd Wagner; Karl-Jürgen Bär
Journal:  Hum Brain Mapp       Date:  2018-09-05       Impact factor: 5.038

2.  New-Onset Psychosis Associated With a Lesion Localized in the Rostral Tectum: Insights Into Pathway-Specific Connectivity Disrupted in Psychosis.

Authors:  Eleftheria Koropouli; Nikos Melanitis; Vasileios I Dimitriou; Asimina Grigoriou; Efstratios Karavasilis; Konstantina S Nikita; Elias Tzavellas; Thomas Paparrigopoulos
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

Review 3.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

4.  Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study.

Authors:  Manon Dubol; Christian Trichard; Claire Leroy; Anca-Larisa Sandu; Mehdi Rahim; Bernard Granger; Eleni T Tzavara; Laurent Karila; Jean-Luc Martinot; Eric Artiges
Journal:  Neuropsychopharmacology       Date:  2017-08-22       Impact factor: 7.853

Review 5.  Future Prospects of Positron Emission Tomography-Magnetic Resonance Imaging Hybrid Systems and Applications in Psychiatric Disorders.

Authors:  Young-Don Son; Young-Bo Kim; Jong-Hoon Kim; Jeong-Hee Kim; Dae-Hyuk Kwon; Haigun Lee; Zang-Hee Cho
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-08

6.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.